MARKET

BPMC

BPMC

Blueprint Medicines Corp
NASDAQ
86.09
+0.91
+1.07%
After Hours: 85.31 -0.78 -0.91% 16:05 04/16 EDT
OPEN
84.51
PREV CLOSE
85.18
HIGH
88.08
LOW
84.44
VOLUME
410.71K
TURNOVER
0
52 WEEK HIGH
101.00
52 WEEK LOW
43.49
MARKET CAP
5.27B
P/E (TTM)
-10.2832
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at BPMC last week (0408-0412)?
Weekly Report · 1d ago
S&P 500 Futures Fall In Premarket Trading; CarMax, Fastenal Lag
U.S. Stock markets set to open in two hours. S&P 500 futures were down 0.39% in pre-market trading. Stocks in Asia were mixed overnight. Bitcoin rose 0.74% to $70,541. Brent crude oil futures were up 0.41%.
Barron‘s · 5d ago
Decoding 6 Analyst Evaluations For Blueprint Medicines
Blueprint Medicines Corp is a biopharmaceutical company. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. 6 analysts have shared their evaluations of Blueprint Medicines in the last three months. The firm has an average price target of $95.67 for the company. It has a 12-month revenue growth of 85.55%.
Benzinga · 6d ago
Blueprint Medicines Price Target Maintained With a $114.00/Share by JMP Securities
Dow Jones · 6d ago
JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target
Benzinga · 6d ago
Blueprint Medicines Buy Rating: Promising BLU-222 Efficacy and Strong Financial Outlook
TipRanks · 04/09 20:25
Weekly Report: what happened at BPMC last week (0401-0405)?
Weekly Report · 04/08 09:28
Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)
Blueprint Medicines Corporation's price-to-sales ratio of 22.3x is higher than the Biotechs industry average. The company has posted a 69% drop in revenue in the last three years. The industry is predicted to grow revenue by 164% per year over the next five years. Blueprint Medicines is trading at a high P/S compared to the industry.
Simply Wall St · 04/05 11:00
More
About BPMC
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Webull offers Blueprint Medicines Corp stock information, including NASDAQ: BPMC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BPMC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BPMC stock methods without spending real money on the virtual paper trading platform.